# A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD

> **NCT05643638** · PHASE2 · RECRUITING · sponsor: **Cynata Therapeutics Limited** · enrollment: 60 (estimated)

## Conditions studied

- Graft Versus Host Disease, Acute

## Interventions

- **BIOLOGICAL:** CYP-001: Cymerus induced pluripotent stem cell (iPSC)-derived mesenchymal stem cells (MSCs)
- **BIOLOGICAL:** Placebo
- **DRUG:** Corticosteroids

## Key facts

- **NCT ID:** NCT05643638
- **Lead sponsor:** Cynata Therapeutics Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-03-04
- **Primary completion:** 2026-03
- **Final completion:** 2027-12
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05643638

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05643638, "A Study of CYP-001 in Combination With Corticosteroids in Adults With High-risk aGvHD". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05643638. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*